{"product_id":"hollandfrei-cancer-medicine-9781119750680","title":"HollandFrei Cancer Medicine","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of contributors xi\u003c\/p\u003e \u003cp\u003ePreface xxvii\u003c\/p\u003e \u003cp\u003eAcknowledgments xxix\u003c\/p\u003e \u003cp\u003ePart 1: INTRODUCTION\u003c\/p\u003e \u003cp\u003e1 Cardinal manifestations of cancer 3\u003c\/p\u003e \u003cp\u003eJames F. Holland, Robert C. Bast, Jr., John C. Byrd,\u003c\/p\u003e \u003cp\u003eCarlo M. Croce, Ernest Hawk, Fadlo R. Khuri, Raphael\u003c\/p\u003e \u003cp\u003eE. Pollock, Apostolia M. Tsimberadou, Christopher G.\u003c\/p\u003e \u003cp\u003eWillett, and Cheryl L.Willman\u003c\/p\u003e \u003cp\u003e2 Biological hallmarks of cancer 7\u003c\/p\u003e \u003cp\u003eDouglas Hanahan and Robert A.Weinberg\u003c\/p\u003e \u003cp\u003ePart 2: TUMOR BIOLOGY\u003c\/p\u003e \u003cp\u003e3 Molecular biology, genetics, and translational\u003c\/p\u003e \u003cp\u003emodels of human cancer 19\u003c\/p\u003e \u003cp\u003eBenno Traub, Florian Scheufele, Srinivas R.\u003c\/p\u003e \u003cp\u003eViswanathan, Matthew Meyerson, and David A. Tuveson\u003c\/p\u003e \u003cp\u003e4 Oncogenes 49\u003c\/p\u003e \u003cp\u003eMarco A. Pierotti, Milo Frattini, Samantha Epistolio,\u003c\/p\u003e \u003cp\u003eGabriella Sozzi, and Carlo M. Croce\u003c\/p\u003e \u003cp\u003e5 Tumor suppressor genes 73\u003c\/p\u003e \u003cp\u003eFred Bunz and Bert Vogelstein\u003c\/p\u003e \u003cp\u003e6 Epigenetic contributions to human cancer 89\u003c\/p\u003e \u003cp\u003eStephen B. Baylin\u003c\/p\u003e \u003cp\u003e7 Cancer genomics and evolution 101\u003c\/p\u003e \u003cp\u003eWilliam P. D. Hendricks, Aleksandar Sekulic, Alan H.\u003c\/p\u003e \u003cp\u003eBryce, Muhammed Murtaza, Pilar Ramos, Jessica D.\u003c\/p\u003e \u003cp\u003eLang, Timothy G. Whitsett, Timothy K. McDaniel,\u003c\/p\u003e \u003cp\u003eRussell C. Rockne, Nicholas Banovich, and Jeffrey M. Trent\u003c\/p\u003e \u003cp\u003e8 Chromosomal aberrations in cancer 125\u003c\/p\u003e \u003cp\u003eMegan E. McNerney, Ari J. Rosenberg, and Michelle M.\u003c\/p\u003e \u003cp\u003eLe Beau\u003c\/p\u003e \u003cp\u003e9 MicroRNA expression in cancer 143\u003c\/p\u003e \u003cp\u003eSerge P. Nana-Sinkam, Mario Acunzo, and Carlo M. Croce\u003c\/p\u003e \u003cp\u003e10 Aberrant signaling pathways in cancer 151\u003c\/p\u003e \u003cp\u003eLuca Grumolato and Stuart A. Aaronson\u003c\/p\u003e \u003cp\u003e11 Differentiation therapy 161\u003c\/p\u003e \u003cp\u003eSai-Juan Chen, Xiao-Jing Yan, Guang-Biao Zhou, and\u003c\/p\u003e \u003cp\u003eZhu Chen\u003c\/p\u003e \u003cp\u003e12 Cancer stem cells 177\u003c\/p\u003e \u003cp\u003eGrace G. Bushnell,Michael D. Brooks, andMax S.Wicha\u003c\/p\u003e \u003cp\u003e13 Cancer and cell death 187\u003c\/p\u003e \u003cp\u003eJohn C. Reed\u003c\/p\u003e \u003cp\u003e14 Cancer cell immortality: targeting telomerase and\u003c\/p\u003e \u003cp\u003etelomeres 201\u003c\/p\u003e \u003cp\u003eIlgen Mender, Zeliha G. Dikmen, and JerryW. Shay\u003c\/p\u003e \u003cp\u003e15 Cancer metabolism 211\u003c\/p\u003e \u003cp\u003eNatalya N. Pavlova, Aparna D. Rao, Ralph J.\u003c\/p\u003e \u003cp\u003eDeBerardinis, and Craig B.Thompson\u003c\/p\u003e \u003cp\u003e16 Tumor angiogenesis 223\u003c\/p\u003e \u003cp\u003eJohn V. Heymach, Amado Zurita-Saavedra, Scott\u003c\/p\u003e \u003cp\u003eKopetz, Tina Cascone, MoniqueNilsson, and IreneGuijarro\u003c\/p\u003e \u003cp\u003ePart 3: QUANTITATIVE ONCOLOGY\u003c\/p\u003e \u003cp\u003e17 Cancer bioinformatics 247\u003c\/p\u003e \u003cp\u003eJohn N.Weinstein\u003c\/p\u003e \u003cp\u003e18 Systems biology and genomics 261\u003c\/p\u003e \u003cp\u003eSaima Hassan, Joe W. Gray, and LauraM.Heiser\u003c\/p\u003e \u003cp\u003e19 Statistical innovations in cancer research 269\u003c\/p\u003e \u003cp\u003eJ. Jack Lee and Donald A. Berry\u003c\/p\u003e \u003cp\u003e20 Biomarker based clinical trial design in the era of\u003c\/p\u003e \u003cp\u003egenomic medicine 285\u003c\/p\u003e \u003cp\u003eR.Donald Harvey, Yuan Liu, Taofeek K.Owonikoko,\u003c\/p\u003e \u003cp\u003eand Suresh S. Ramalingam\u003c\/p\u003e \u003cp\u003e21 Clinical and research informatics data strategy for\u003c\/p\u003e \u003cp\u003eprecision oncology 293\u003c\/p\u003e \u003cp\u003eDouglas Hartman, Uma Chandran, Michael Davis,\u003c\/p\u003e \u003cp\u003eRajiv Dhir,William E. Shirey, Jonathan C. Silverstein,\u003c\/p\u003e \u003cp\u003eand Michael J. Becich\u003c\/p\u003e \u003cp\u003ePart 4: CARCINOGENESIS\u003c\/p\u003e \u003cp\u003e22 Chemical carcinogenesis 305\u003c\/p\u003e \u003cp\u003eLorne J. Hofseth, AinsleyWeston, and Curtis C. Harris\u003c\/p\u003e \u003cp\u003e23 Ionizing radiation 325\u003c\/p\u003e \u003cp\u003eDavid J. Grdina\u003c\/p\u003e \u003cp\u003e24 Ultraviolet radiation carcinogenesis 333\u003c\/p\u003e \u003cp\u003eJames E. Cleaver, Susana Ortiz-Urda, and Sarah Arron\u003c\/p\u003e \u003cp\u003e25 Inflammation and cancer 339\u003c\/p\u003e \u003cp\u003eJelena Todoric, Atsushi Umemura, Koji Taniguchi, and\u003c\/p\u003e \u003cp\u003eMichael Karin\u003c\/p\u003e \u003cp\u003e26 RNA tumor viruses 347\u003c\/p\u003e \u003cp\u003eRobert C. Gallo and Marvin S. Reitz\u003c\/p\u003e \u003cp\u003e27 Herpesviruses 359\u003c\/p\u003e \u003cp\u003eJeffrey I. Cohen\u003c\/p\u003e \u003cp\u003e28 Papillomaviruses and cervical neoplasia 367\u003c\/p\u003e \u003cp\u003eMichael F. Herfs, Christopher P. Crum, and KarlMunger\u003c\/p\u003e \u003cp\u003e29 Hepatitis viruses and hepatoma 373\u003c\/p\u003e \u003cp\u003eHongyangWang\u003c\/p\u003e \u003cp\u003e30 Parasites 379\u003c\/p\u003e \u003cp\u003eMervat El Azzouni, Charbel F. Matar, Radwa Galal,\u003c\/p\u003e \u003cp\u003eElio Jabra, and Ali Shamseddine\u003c\/p\u003e \u003cp\u003ePart 5: EPIDEMIOLOGY, PREVENTION, AND\u003c\/p\u003e \u003cp\u003eDETECTION\u003c\/p\u003e \u003cp\u003e31 Cancer epidemiology 391\u003c\/p\u003e \u003cp\u003eVeronika Fedirko, Kevin T. Nead, Carrie Daniel, and\u003c\/p\u003e \u003cp\u003ePaul Scheet\u003c\/p\u003e \u003cp\u003e32 Hereditary cancer syndromes: risk assessment and\u003c\/p\u003e \u003cp\u003egenetic counseling 403\u003c\/p\u003e \u003cp\u003eRachel Bluebond, Sarah A. Bannon, Samuel M. Hyde,\u003c\/p\u003e \u003cp\u003eAshley H.Woodson, Nancy Y.-Q. You, Karen H. Lu, and\u003c\/p\u003e \u003cp\u003eBanu Arun\u003c\/p\u003e \u003cp\u003e33 Behavioral approaches to cancer prevention 425\u003c\/p\u003e \u003cp\u003eRoberto Gonzalez and Maher Karam-Hage\u003c\/p\u003e \u003cp\u003e34 Diet and nutrition in the etiology and prevention\u003c\/p\u003e \u003cp\u003eof cancer 433\u003c\/p\u003e \u003cp\u003eSteven K. Clinton, Edward L. Giovannucci, Fred K.\u003c\/p\u003e \u003cp\u003eTabung, and Elizabeth M. Grainger\u003c\/p\u003e \u003cp\u003e35 Chemoprevention of cancer 453\u003c\/p\u003e \u003cp\u003eErnest Hawk, Karen C. Maresso, Powel Brown, Michelle\u003c\/p\u003e \u003cp\u003eI. Savage, and Scott M. Lippman\u003c\/p\u003e \u003cp\u003e36 Cancer screening and early detection 473\u003c\/p\u003e \u003cp\u003eOtisW. Brawley\u003c\/p\u003e \u003cp\u003ePart 6: CLINICAL DISCIPLINES\u003c\/p\u003e \u003cp\u003e37 Clinical cancer genomic diagnostics and modern\u003c\/p\u003e \u003cp\u003ediagnostic pathology 493\u003c\/p\u003e \u003cp\u003eKatherine Roth, Stephen B. Gruber, and Kevin McDonnell\u003c\/p\u003e \u003cp\u003e38 Molecular diagnostics in cancer 505\u003c\/p\u003e \u003cp\u003eZachary L. Coyne, Roshni D. Kalachand, Robert C. Bast\u003c\/p\u003e \u003cp\u003eJr., Gordon B. Mills, and Bryan T. Hennessy\u003c\/p\u003e \u003cp\u003e39 Principles of imaging 519\u003c\/p\u003e \u003cp\u003eLawrence H. Schwartz\u003c\/p\u003e \u003cp\u003e40 Interventional radiology for the cancer patient 521\u003c\/p\u003e \u003cp\u003eZeyad A. Metwalli, Judy U. Ahrar, andMichael J. Wallace\u003c\/p\u003e \u003cp\u003e41 Principles of surgical oncology 531\u003c\/p\u003e \u003cp\u003eToddW. Bauer, Kenneth K. Tanabe, and Raphael E. Pollock\u003c\/p\u003e \u003cp\u003e42 Principles of radiation oncology 543\u003c\/p\u003e \u003cp\u003eScott R. Floyd, Justus Adamson, Philip P. Connell, Ralph\u003c\/p\u003e \u003cp\u003eR.Weichselbaum, and Christopher G.Willett\u003c\/p\u003e \u003cp\u003e43 Principles of medical oncology 553\u003c\/p\u003e \u003cp\u003eApostolia M. Tsimberidou, Robert C. Bast, Jr., Fadlo R.\u003c\/p\u003e \u003cp\u003eKhuri, and John C. Byrd\u003c\/p\u003e \u003cp\u003e44 Pain and palliative care 567\u003c\/p\u003e \u003cp\u003eLaura Van Metre Baum and Cardinale B. Smith\u003c\/p\u003e \u003cp\u003e45 Psycho-oncology 577\u003c\/p\u003e \u003cp\u003eDiya Banerjee and Andrew J. Roth\u003c\/p\u003e \u003cp\u003e46 Principles of cancer rehabilitation medicine 585\u003c\/p\u003e \u003cp\u003eMichael D. Stubblefield, Miguel Escalon, Sofia A.\u003c\/p\u003e \u003cp\u003eBarchuk, Krina Vyas, and David C.Thomas\u003c\/p\u003e \u003cp\u003e47 Integrative oncology in cancer care 593\u003c\/p\u003e \u003cp\u003eGabriel Lopez,Wenli Liu, Santhosshi Narayanan, and\u003c\/p\u003e \u003cp\u003eLorenzo Cohen\u003c\/p\u003e \u003cp\u003e48 Health services research 599\u003c\/p\u003e \u003cp\u003eMichaela A. Dinan and Devon K. Check\u003c\/p\u003e \u003cp\u003ePart 7: INDIVIDUALIZED TREATMENT\u003c\/p\u003e \u003cp\u003e49 Precision medicine in oncology drug development 613\u003c\/p\u003e \u003cp\u003eApostolia M. Tsimberidou, Elena Fountzilas, and\u003c\/p\u003e \u003cp\u003eRazelle Kurzrock\u003c\/p\u003e \u003cp\u003ePart 8: CHEMOTHERAPY\u003c\/p\u003e \u003cp\u003e50 Drug development of small molecule cancer\u003c\/p\u003e \u003cp\u003etherapeutics in an Academic Cancer Center 631\u003c\/p\u003e \u003cp\u003eChristopher C. Coss, Jeffrey T. Patrick, Damien Gerald,\u003c\/p\u003e \u003cp\u003eGerard Hilinski, Reena Shakya, and John C. Byrd\u003c\/p\u003e \u003cp\u003e51 Principles of dose, schedule, and combination\u003c\/p\u003e \u003cp\u003etherapy 641\u003c\/p\u003e \u003cp\u003eJoseph P. Eder and Navid Hafez\u003c\/p\u003e \u003cp\u003e52 Pharmacology of small-molecule anticancer agents 655\u003c\/p\u003e \u003cp\u003eZahra Talebi, Sharyn D. Baker, and Alex Sparreboom\u003c\/p\u003e \u003cp\u003e53 Folate antagonists 667\u003c\/p\u003e \u003cp\u003eLisa Gennarini, Peter D. Cole, and Joseph R. Bertino\u003c\/p\u003e \u003cp\u003e54 Pyrimidine and purine antimetabolites 679\u003c\/p\u003e \u003cp\u003eRobert B. Diasio and StevenM. Offer\u003c\/p\u003e \u003cp\u003e55 Alkylating agents and platinum antitumor\u003c\/p\u003e \u003cp\u003ecompounds 693\u003c\/p\u003e \u003cp\u003eZahid H. Siddik\u003c\/p\u003e \u003cp\u003e56 DNA topoisomerase targeting drugs 701\u003c\/p\u003e \u003cp\u003eAnishThomas, Susan Bates,William D. Figg, Sr., and\u003c\/p\u003e \u003cp\u003eYves Pommier\u003c\/p\u003e \u003cp\u003e57 Microtubule inhibitors 717\u003c\/p\u003e \u003cp\u003eGiuseppe Galletti and Paraskevi Giannakakou\u003c\/p\u003e \u003cp\u003e58 Drug resistance and its clinical circumvention 731\u003c\/p\u003e \u003cp\u003eJeffrey A. Moscow, Shannon K. Hughes, Kenneth H.\u003c\/p\u003e \u003cp\u003eCowan, and Branimir I. Sikic\u003c\/p\u003e \u003cp\u003ePart 9: BIOLOGICAL AND GENE THERAPY\u003c\/p\u003e \u003cp\u003e59 Cytokines, interferons, and hematopoietic growth\u003c\/p\u003e \u003cp\u003efactors 739\u003c\/p\u003e \u003cp\u003eNarendranath Epperla,Walter Hanel, and Moshe Talpaz\u003c\/p\u003e \u003cp\u003e60 Monoclonal antibody and targeted toxin therapy 755\u003c\/p\u003e \u003cp\u003eRobert C. Bast, Jr. andMichael R. Zalutsky\u003c\/p\u003e \u003cp\u003e61 Vaccines and immunomodulators 781\u003c\/p\u003e \u003cp\u003eJeffrey Schlom, Sofia R. Gameiro, Claudia Palena, and\u003c\/p\u003e \u003cp\u003eJames L. Gulley\u003c\/p\u003e \u003cp\u003e62 T cell immunotherapy of cancer 789\u003c\/p\u003e \u003cp\u003eM. Lia Palomba, Jae H. Park, and Renier Brentjens\u003c\/p\u003e \u003cp\u003e63 Cancer immunotherapy 799\u003c\/p\u003e \u003cp\u003ePadmanee Sharma, Swetha Anandhan, Bilal A.\u003c\/p\u003e \u003cp\u003eSiddiqui, Sangeeta Goswami, Sumit K. Subudhi, Jianjun\u003c\/p\u003e \u003cp\u003eGao, Karl Peggs, Sergio Quezada, and James P. Allison\u003c\/p\u003e \u003cp\u003e64 Cancer gene therapy 817\u003c\/p\u003e \u003cp\u003eHaruko Tashiro, Lauren Scherer, and Malcolm Brenner\u003c\/p\u003e \u003cp\u003e65 Cancer nanotechnology 825\u003c\/p\u003e \u003cp\u003eXingya Jiang, Yanlan Liu, Danny Liu, Jinjun Shi, and\u003c\/p\u003e \u003cp\u003eRobert Langer\u003c\/p\u003e \u003cp\u003e66 Hematopoietic cell transplantation 833\u003c\/p\u003e \u003cp\u003eQaiser Bashir, Elizabeth J. Shpall, and Richard E. Champlin\u003c\/p\u003e \u003cp\u003ePart 10: SPECIAL POPULATIONS\u003c\/p\u003e \u003cp\u003e67 Principles of pediatric oncology 847\u003c\/p\u003e \u003cp\u003eTheodore P. Nicolaides, Elizabeth Raetz, andWilliam L.\u003c\/p\u003e \u003cp\u003eCarroll\u003c\/p\u003e \u003cp\u003e68 Cancer and pregnancy 867\u003c\/p\u003e \u003cp\u003eJennifer K. Litton\u003c\/p\u003e \u003cp\u003e69 Cancer and aging 877\u003c\/p\u003e \u003cp\u003eAshley E. Rosko, Carolyn J. Presley, Grant R.Williams,\u003c\/p\u003e \u003cp\u003eand Rebecca L. Olin\u003c\/p\u003e \u003cp\u003e70 Disparities in cancer care 885\u003c\/p\u003e \u003cp\u003eOtisW. Brawley\u003c\/p\u003e \u003cp\u003e71 Neoplasms in people living with human\u003c\/p\u003e \u003cp\u003eimmunodeficiency virus 895\u003c\/p\u003e \u003cp\u003eChia-Ching J.Wang and Elizabeth Y. Chiao\u003c\/p\u003e \u003cp\u003e72 Cancer survivorship 911\u003c\/p\u003e \u003cp\u003eLewis Foxhall\u003c\/p\u003e \u003cp\u003ePart 11: DISEASE SITES\u003c\/p\u003e \u003cp\u003e73 Primary neoplasms of the brain in adults 921\u003c\/p\u003e \u003cp\u003eMatthew A. Smith-Cohn and Mark R. Gilbert\u003c\/p\u003e \u003cp\u003e74 Neoplasms of the eye and orbit 933\u003c\/p\u003e \u003cp\u003eErica R. Alvarez, Claudia M. Prospero Ponce, Patricia\u003c\/p\u003e \u003cp\u003eChevez-Barrios, and Dan S. Gombos\u003c\/p\u003e \u003cp\u003e75 Neoplasms of the endocrine glands and pituitary\u003c\/p\u003e \u003cp\u003eneoplasms 943\u003c\/p\u003e \u003cp\u003eRui Feng, Chirag D. Gandhi, Margaret Pain, and\u003c\/p\u003e \u003cp\u003eKalmon D. Post\u003c\/p\u003e \u003cp\u003e76 Neoplasms of the thyroid 949\u003c\/p\u003e \u003cp\u003eMatthew D. Ringel\u003c\/p\u003e \u003cp\u003e77 Malignant tumors of the adrenal gland 961\u003c\/p\u003e \u003cp\u003eJeffrey E. Lee, Mouhammed A. Habra, andMatthew T.\u003c\/p\u003e \u003cp\u003eCampbell\u003c\/p\u003e \u003cp\u003e78 Tumors of the diffuse neuroendocrine and\u003c\/p\u003e \u003cp\u003egastroenteropancreatic system 971\u003c\/p\u003e \u003cp\u003eEvan Vosburgh\u003c\/p\u003e \u003cp\u003e79 Neoplasms of the head and neck 981\u003c\/p\u003e \u003cp\u003eRobert L. Ferris, AdamS. Garden, andNabil F. Saba\u003c\/p\u003e \u003cp\u003e80 Cancer of the lung 1005\u003c\/p\u003e \u003cp\u003eDaniel Morgensztern, Daniel Boffa, Alexander Chen,\u003c\/p\u003e \u003cp\u003eAndrew Dhanasopon, Sarah B. Goldberg, Roy H.\u003c\/p\u003e \u003cp\u003eDecker, Siddhartha Devarakonda, Jane P. Ko, Luisa M.\u003c\/p\u003e \u003cp\u003eSolis Soto, Saiama N.Waqar, Ignacio I.Wistuba, and\u003c\/p\u003e \u003cp\u003eRoy S. Herbst\u003c\/p\u003e \u003cp\u003e81 Malignant pleural mesothelioma 1029\u003c\/p\u003e \u003cp\u003eMichele Carbone, Daniel R. Gomez, Anne S. Tsao,\u003c\/p\u003e \u003cp\u003eHaining Yang, and Harvey I. Pass\u003c\/p\u003e \u003cp\u003e82 Thymomas and thymic tumors 1043\u003c\/p\u003e \u003cp\u003eMayur D. Mody,Gabriel L. Sica, Suresh S. Ramalingam,\u003c\/p\u003e \u003cp\u003eand Dong M. Shin\u003c\/p\u003e \u003cp\u003e83 Tumors of the heart and great vessels 1055\u003c\/p\u003e \u003cp\u003eMoritz C.Wyler von Ballmoos and Michael J. Reardon\u003c\/p\u003e \u003cp\u003e84 Primary germ cell tumors of the thorax 1061\u003c\/p\u003e \u003cp\u003eJohn D. Hainsworth and Frank A. Greco\u003c\/p\u003e \u003cp\u003e85 Neoplasms of the esophagus 1065\u003c\/p\u003e \u003cp\u003eMaxW. Sung and Virginia R. Litle\u003c\/p\u003e \u003cp\u003e86 Carcinoma of the stomach 1083\u003c\/p\u003e \u003cp\u003eCarl Schmidt, Nour Daboul, Carly Likar, and JoshuaWeir\u003c\/p\u003e \u003cp\u003e87 Primary neoplasms of the liver 1095\u003c\/p\u003e \u003cp\u003eHop S. Tran Cao, Junichi Shindoh, and Jean-Nicolas\u003c\/p\u003e \u003cp\u003eVauthey\u003c\/p\u003e \u003cp\u003e88 Gallbladder and bile duct cancer 1109\u003c\/p\u003e \u003cp\u003eMariam F. Eskander, Christopher T. Aquina, and\u003c\/p\u003e \u003cp\u003eTimothy M. Pawlik\u003c\/p\u003e \u003cp\u003e89 Neoplasms of the exocrine pancreas 1123\u003c\/p\u003e \u003cp\u003eRobert A. Wolff, Donghui Li, AnirbanMaitra, Susan\u003c\/p\u003e \u003cp\u003eTsai, Eugene Koay, and Douglas B. Evans\u003c\/p\u003e \u003cp\u003e90 Neoplasms of the appendix and peritoneum 1139\u003c\/p\u003e \u003cp\u003eAnnie Liu, Diana Cardona, and Dan Blazer\u003c\/p\u003e \u003cp\u003e91 Carcinoma of the colon and rectum 1147\u003c\/p\u003e \u003cp\u003eYota Suzuki, Douglas S. Tyler, and Uma R. Phatak\u003c\/p\u003e \u003cp\u003e92 Neoplasms of the anus 1169\u003c\/p\u003e \u003cp\u003eAlexandre A. A. Jácome and Cathy Eng\u003c\/p\u003e \u003cp\u003e93 Renal cell carcinoma 1181\u003c\/p\u003e \u003cp\u003eClaude M. Grigg, Earle F. Burgess, Stephen B. Riggs,\u003c\/p\u003e \u003cp\u003eJason Zhu, and Derek Raghavan\u003c\/p\u003e \u003cp\u003e94 Urothelial cancer 1191\u003c\/p\u003e \u003cp\u003eDerek Raghavan, Richard Cote, Earle F. Burgess, Derek\u003c\/p\u003e \u003cp\u003eMcHaffie, and Peter E. Clark\u003c\/p\u003e \u003cp\u003e95 Neoplasms of the prostate 1201\u003c\/p\u003e \u003cp\u003eAna Aparicio, Patrick Pilie, Devaki S. Surasi, Seungtaek\u003c\/p\u003e \u003cp\u003eChoi, Brian F. Chapin, Christopher J. Logothetis, and\u003c\/p\u003e \u003cp\u003ePaul G. Corn\u003c\/p\u003e \u003cp\u003e96 Tumors of the penis and the urethra 1239\u003c\/p\u003e \u003cp\u003eJad Chahoud, Andrea Necchi, and Philippe E. Spiess\u003c\/p\u003e \u003cp\u003e97 Testis cancer 1245\u003c\/p\u003e \u003cp\u003eMichael Hawking, Gladell Paner, Scott Eggener, and\u003c\/p\u003e \u003cp\u003eWalter M. Stadler\u003c\/p\u003e \u003cp\u003e98 Neoplasms of the vulva and vagina 1261\u003c\/p\u003e \u003cp\u003eMichael Frumovitz and Summer B. Dewdney\u003c\/p\u003e \u003cp\u003e99 Neoplasms of the cervix 1275\u003c\/p\u003e \u003cp\u003eAnuja Jhingran\u003c\/p\u003e \u003cp\u003e100 Endometrial cancer 1299\u003c\/p\u003e \u003cp\u003eShannon N.Westin, Karen Lu, and Jamal Rahaman\u003c\/p\u003e \u003cp\u003e101 Epithelial ovarian, fallopian tube, and peritoneal\u003c\/p\u003e \u003cp\u003ecancer 1311\u003c\/p\u003e \u003cp\u003eJonathan S. Berek, Malte Renz, Michael L. Friedlander,\u003c\/p\u003e \u003cp\u003eand Robert C. Bast, Jr.\u003c\/p\u003e \u003cp\u003e102 Nonepithelial ovarian malignancies 1329\u003c\/p\u003e \u003cp\u003eJonathan S. Berek, Malte Renz, Michael L. Friedlander,\u003c\/p\u003e \u003cp\u003eand Robert C. Bast, Jr.\u003c\/p\u003e \u003cp\u003e103 Molar pregnancy and gestational trophoblastic\u003c\/p\u003e \u003cp\u003eneoplasia 1343\u003c\/p\u003e \u003cp\u003eNeil S. Horowitz, Donald P. Goldstein, and Ross S. Berkowitz\u003c\/p\u003e \u003cp\u003e104 Gynecologic sarcomas 1351\u003c\/p\u003e \u003cp\u003eJamal Rahaman and Carmel J. Cohen\u003c\/p\u003e \u003cp\u003e105 Neoplasms of the breast 1361\u003c\/p\u003e \u003cp\u003eDebu Tripathy, Sukh Makhnoon, Banu Arun, Aysegul\u003c\/p\u003e \u003cp\u003eSahin, Nicole M. Kettner, Senthil Damodaran, Khandan\u003c\/p\u003e \u003cp\u003eKeyomarsi,Wei Yang, Kelly K. Hunt, Mark Clemens,\u003c\/p\u003e \u003cp\u003eWendy A. Woodward, Melissa P.Mitchell, Rachel\u003c\/p\u003e \u003cp\u003eLayman, Evthokia A. Hobbs, Bora Lim, MeganDupuis,\u003c\/p\u003e \u003cp\u003eRashmi Murthy, Omar Alhalabi, Nuhad Ibrahim,\u003c\/p\u003e \u003cp\u003eIshwaria M. Subbiah, and Carlos Barcenas\u003c\/p\u003e \u003cp\u003e106 Malignant melanoma 1413\u003c\/p\u003e \u003cp\u003eMichael J. Carr, JustinM. Ko, SusanM. Swetter, Scott E.\u003c\/p\u003e \u003cp\u003eWoodman, Vernon K. Sondak, Kim A. Margolin, and\u003c\/p\u003e \u003cp\u003eJonathan S. Zager\u003c\/p\u003e \u003cp\u003e107 Other skin cancers 1437\u003c\/p\u003e \u003cp\u003eStacy L. McMurray,William G. Stebbins, Eric A.\u003c\/p\u003e \u003cp\u003eMillican, and Victor A. Neel\u003c\/p\u003e \u003cp\u003e108 Bone tumors 1451\u003c\/p\u003e \u003cp\u003eTimothy A. Damron\u003c\/p\u003e \u003cp\u003e109 Soft tissue sarcomas 1477\u003c\/p\u003e \u003cp\u003eKatherine A.Thornton, Elizabeth H. Baldini, Robert G.\u003c\/p\u003e \u003cp\u003eMaki, Brian O’Sullivan, Yan Leyfman, and Chandrajit P. Raut\u003c\/p\u003e \u003cp\u003e110 Myelodysplastic syndromes 1501\u003c\/p\u003e \u003cp\u003eUma M. Borate\u003c\/p\u003e \u003cp\u003e111 Acute myeloid leukemia in adults: mast cell\u003c\/p\u003e \u003cp\u003eleukemia and other mast cell neoplasms 1517\u003c\/p\u003e \u003cp\u003eRichardM. Stone, Charles A. Schiffer, and Daniel J. DeAngelo\u003c\/p\u003e \u003cp\u003e112 Chronic myeloid leukemia 1537\u003c\/p\u003e \u003cp\u003eJorge Cortes, Richard T. Silver, and Hagop Kantarjian\u003c\/p\u003e \u003cp\u003e113 Acute lymphoblastic leukemia 1547\u003c\/p\u003e \u003cp\u003eElias Jabbour, Nitin Jain, Hagop Kantarjian, and Susan\u003c\/p\u003e \u003cp\u003eO’Brien\u003c\/p\u003e \u003cp\u003e114 Chronic lymphocytic leukemia 1559\u003c\/p\u003e \u003cp\u003eJacqueline C. Barrientos, Kanti R. Rai, and Joanna M. Rhodes\u003c\/p\u003e \u003cp\u003e115 Hodgkin lymphoma 1569\u003c\/p\u003e \u003cp\u003eDavid J. Straus and Anita Kumar\u003c\/p\u003e \u003cp\u003e116 Clonal hematopoiesis in cancer 1579\u003c\/p\u003e \u003cp\u003ePhilipp J. Rauch and David P. Steensma\u003c\/p\u003e \u003cp\u003e117 Non-Hodgkin’s lymphoma 1587\u003c\/p\u003e \u003cp\u003eArnold S. Freedman and Ann S. LaCasce\u003c\/p\u003e \u003cp\u003e118 Mycosis fungoides and Sézary syndrome 1603\u003c\/p\u003e \u003cp\u003eWalter Hanel, Catherine Chung, and John C. Reneau\u003c\/p\u003e \u003cp\u003e119 Plasma cell disorders 1611\u003c\/p\u003e \u003cp\u003eAndrew J. Yee, Teru Hideshima, Noopur Raje, and\u003c\/p\u003e \u003cp\u003eKenneth C. Anderson\u003c\/p\u003e \u003cp\u003e120 Myeloproliferative disorders 1633\u003c\/p\u003e \u003cp\u003eJeanne Palmer and Ruben Mesa\u003c\/p\u003e \u003cp\u003ePart 12: MANAGEMENT OF CANCER\u003c\/p\u003e \u003cp\u003eCOMPLICATIONS\u003c\/p\u003e \u003cp\u003e121 Neoplasms of unknown primary site 1647\u003c\/p\u003e \u003cp\u003eJohn D. Hainsworth and Frank A. Greco\u003c\/p\u003e \u003cp\u003e122 Cancer cachexia 1659\u003c\/p\u003e \u003cp\u003eAssaad A. Eid, Rachel Njeim, Fadlo R. Khuri, and\u003c\/p\u003e \u003cp\u003eDavid K.Thomas\u003c\/p\u003e \u003cp\u003e123 Antiemetic therapy 1673\u003c\/p\u003e \u003cp\u003eMichael J. Berger andDavid S. Ettinger\u003c\/p\u003e \u003cp\u003e124 Neurologic complications of cancer 1683\u003c\/p\u003e \u003cp\u003eLuis Nicolas Gonzalez Castro, Tracy T. Batchelor, and\u003c\/p\u003e \u003cp\u003eLisa M. DeAngelis\u003c\/p\u003e \u003cp\u003e125 Dermatologic complications of cancer\u003c\/p\u003e \u003cp\u003echemotherapy 1701\u003c\/p\u003e \u003cp\u003eAnisha B. Patel, Padmavathi V. Karri, and Madeleine Duvic\u003c\/p\u003e \u003cp\u003e126 Skeletal complications 1715\u003c\/p\u003e \u003cp\u003eMichael A. Via, Ilya Iofin, Jerry Liu, and Jeffrey I. Mechanick\u003c\/p\u003e \u003cp\u003e127 Hematologic complications and blood bank\u003c\/p\u003e \u003cp\u003esupport 1729\u003c\/p\u003e \u003cp\u003eRoger Belizaire and Kenneth C. Anderson\u003c\/p\u003e \u003cp\u003e128 Coagulation complications of cancer patients 1739\u003c\/p\u003e \u003cp\u003eTzu-FeiWang and Kristin Sanfilippo\u003c\/p\u003e \u003cp\u003e129 Urologic complications related to cancer and its\u003c\/p\u003e \u003cp\u003etreatment 1747\u003c\/p\u003e \u003cp\u003eOmar Alhalabi, Ala Abudayyeh, and Nizar M. Tannir\u003c\/p\u003e \u003cp\u003e130 Cardiac complications 1757\u003c\/p\u003e \u003cp\u003eMichael S. Ewer, Steven M. Ewer, andThomas M. Suter\u003c\/p\u003e \u003cp\u003e131 Respiratory complications 1779\u003c\/p\u003e \u003cp\u003eVickie R. Shannon, George A. Eapen, Carlos A. Jimenez,\u003c\/p\u003e \u003cp\u003eHoriana B. Grosu, Rodolfo C. Morice, Lara Bashoura,\u003c\/p\u003e \u003cp\u003eAjay Sheshadre, Scott E. Evans, Roberto Adachi,\u003c\/p\u003e \u003cp\u003eMichael Kroll, Saadia A. Faiz, Diwakar\u003c\/p\u003e \u003cp\u003eD. Balachandran, Selvaraj E. Pravinkumar,\u003c\/p\u003e \u003cp\u003eand Burton F. Dickey\u003c\/p\u003e \u003cp\u003e132 Gastrointestinal and hepatic complications in\u003c\/p\u003e \u003cp\u003ecancer patients 1811\u003c\/p\u003e \u003cp\u003eRobert S. Bresalier, Emmanuel S. Coronel, and Hao Chi Zhang\u003c\/p\u003e \u003cp\u003e133 Oral complications of cancer and their treatment 1827\u003c\/p\u003e \u003cp\u003eStephen T. Sonis, Anna Yuan, and Alessandro Villa\u003c\/p\u003e \u003cp\u003e134 Gonadal complications 1839\u003c\/p\u003e \u003cp\u003eRobertW. Lentz and Catherine E. Klein\u003c\/p\u003e \u003cp\u003e135 Sexual dysfunction 1849\u003c\/p\u003e \u003cp\u003eLeslie R. Schover\u003c\/p\u003e \u003cp\u003e136 Endocrine complications and paraneoplastic\u003c\/p\u003e \u003cp\u003esyndromes 1855\u003c\/p\u003e \u003cp\u003eSai-Ching J. Yeung and Robert F. Gagel\u003c\/p\u003e \u003cp\u003e137 Infections in patients with cancer 1869\u003c\/p\u003e \u003cp\u003eHarrys A. Torres, Dimitrios P. Kontoyiannis, and\u003c\/p\u003e \u003cp\u003eKenneth V.I. Rolston\u003c\/p\u003e \u003cp\u003e138 Oncologic emergencies 1883\u003c\/p\u003e \u003cp\u003eSai-Ching J. Yeung and Carmen P. Escalante\u003c\/p\u003e \u003cp\u003ePart 13: THE FUTURE OF ONCOLOGY\u003c\/p\u003e \u003cp\u003e139 A vision for twenty-first century healthcare 1907\u003c\/p\u003e \u003cp\u003eLeroy Hood, Nathan D. Price, and James T. Yurkovich\u003c\/p\u003e \u003cp\u003eIndex 1915\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407138267479,"sku":"9781119750680","price":274.5,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119750680.jpg?v=1730498313","url":"https:\/\/bookcurl.com\/products\/hollandfrei-cancer-medicine-9781119750680","provider":"Book Curl","version":"1.0","type":"link"}